Liposomal irinotecan pancreatic cancer
「Liposomal irinotecan pancreatic cancer」熱門搜尋資訊
「Liposomal irinotecan pancreatic cancer」文章包含有：「Clinicaloutcomesofliposomalirinotecaninadvanced...」、「First」、「Liposomalirinotecan(Onivyde)」、「LiposomalIrinotecanintheTreatmentofRefractory...」、「LiposomalIrinotecanShowsaLargerTherapeuticIndex...」、「LiposomalIrinotecan」、「NAPOLI」、「ONIVYDE®(irinotecanliposomeinjection)」、「Prioririnotecanexposuredoesnotprecludebenefitto...」、「SubgroupanalysisoftheNAPOLI」
查看更多
Clinical outcomes of liposomal irinotecan in advanced ...
https://www.ncbi.nlm.nih.gov
The efficacy of combination chemotherapy beyond the first-line setting remains modest in patients with advanced pancreatic adenocarcinoma (PAC).
First
https://dailynews.ascopubs.org
Key Points: ... Liposomal irinotecan given with 5-fluorouracil/leucovorin is currently approved for the treatment of patients with metastatic ...
Liposomal irinotecan (Onivyde)
https://pubmed.ncbi.nlm.nih.go
However, irinotecan has not been successfully introduced as a second-line treatment for pancreatic cancer and few randomized clinical studies have evaluated its ...
Liposomal Irinotecan in the Treatment of Refractory ...
https://pubmed.ncbi.nlm.nih.go
Effective therapies against metastatic pancreatic cancer remain limited, and despite treatment, many will ultimately progress. Previously, few options were ...
Liposomal Irinotecan Shows a Larger Therapeutic Index ...
https://www.ncbi.nlm.nih.gov
Irinotecan (CPT-11) is a chemotherapeutic agent used to treat pancreatic cancer. Both irinotecan and its active metabolite SN-38 (converted by ...
Liposomal Irinotecan
https://www.ncbi.nlm.nih.gov
Liposomal irinotecan, in combination with 5-FU/LV, is the first agent to be specifically approved for use in patients with mPDAC who have ...
NAPOLI
https://www.ejcancer.com
Final analysis of NAPOLI-1 trial of liposomal irinotecan confirmed primary analysis. •. Longer overall survival in metastatic pancreatic cancer ...
ONIVYDE® (irinotecan liposome injection)
https://www.onivyde.com
Prior irinotecan exposure does not preclude benefit to ...
https://www.ncbi.nlm.nih.gov
Liposomal irinotecan + 5‐FU/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics ...
Subgroup analysis of the NAPOLI
https://pubmed.ncbi.nlm.nih.go
The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin ...